Chemotherapy resistance and oncogene expression in non-small cell lung cancer

Journal of Thoracic and Cardiovascular Surgery

Volumn 133, Issue 2, 2007, Pages 352-363

  d'Amato, Thomas A ^a   Landreneau, Rodney J ^b   Ricketts, William ^c   Huang, Weidong ^c   Parker, Ricardo ^c   Mechetner, Eugene ^c   Yu, Ing Ru ^c   Luketich, James D ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^c Oncotech Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GROWTH FACTOR RECEPTOR; NAVELBINE; PACLITAXEL; PROTEIN P53;

ANEUPLOIDY; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; ONCOGENE; PLOIDY; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; MALE; ONCOGENES; PLOIDIES; PROBABILITY; SENSITIVITY AND SPECIFICITY; TAXOIDS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VINBLASTINE;

EID: 33846375747     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2006.10.019     Document Type: Article

References (34)

1. American Cancer Society cancer facts and figures 2006 (2006), American Cancer Society, Atlanta 13-15
2. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
3. Strauss G.M., Herndon J., Maddaus M.A., et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633. ASCO Annual Meeting Proceedings, New Orleans. J Clin Oncol 22 (2004) 7019
4. Winton T.L., Livingston R., Johnson D., et al. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10. N Engl J Med 352 (2005) 2289-2297
5. Douillard J., Rosell R., Delena M., et al., Adjuvant Navelbine International Trialist Association. ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): final results after 70-month median follow-up. J Clin Oncol 23 (2005) 7013 ASCO Annual Meeting Proceedings, Orlando [FL]
6. Langer C.J., Stephenson P., Thor A., et al. Trastuzumab in the treatment of advanced non-small cell lung cancer: is there are role?. Focus on Eastern Cooperative Oncology Group Study 2598. J Clin Oncol 22 (2004) 1180-1187
7. Kern D., and Weisenthal L. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 82 (1990) 582-588
8. Mehta R., Bomstein R., Yu I.-R., et al. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Cancer Res Treat 66 (2001) 225-237
9. Loizzi V., Chan J., Osann K., et al. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol 189 (2003) 1301-1307
10. Holloway R., Mehta R., Finkler N., et al. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol 87 (2002) 8-16
11. d'Amato T., Landreneau R., McKenna R., et al. Prevalence of in vitro extreme chemotherapy resistance in resected non-small cell lung cancer. Ann Thorac Surg 81 (2006) 440-446
12. Hedley D., Clark G., Cornelisse C., et al. DNA cytometry consensus conference consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Breast Cancer Res Treat 28 (1993) 55-59
13. Stoetzer O., Munker R., Darsow M., and Wilmanns W. P53-immunoreactive cells in benign and malignant effusions: diagnostic value using a panel of monoclonal antibodies and comparison with CEA-staining. Oncol Rep 6 (1999) 455-458
14. Mechetner E., Kyshtoobayeva A., Zonis S., et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 4 (1998) 389-398
15. Schrag D., Garewal H., Burstein H., et al. American Society of Clinical Oncology technology assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 22 (2004) 3631-3638
16. Samson D., Seidenfeld J., Ziegler K., et al. Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 22 (2004) 3618-3630
17. Fruehauf J., and Alberts D. In vitro drug resistance versus chemosensitivity: two sides of different coins. J Clin Oncol 23 (2005) 3641-3643
18. Nagourney R. Chemotherapy sensitivity and resistance assays: a systemic review?. J Clin Oncol 23 (2005) 3640-3641
19. Medicare Coverage: MCAC Laboratory and Diagnostic Services Panel Human Tumor Assay Systems. Minutes of November 15-16, 1999, Meeting. http://www.cms.hhs.gov/mcd/viewmcac.asp?where=basket&mid=14&basket=mcac:14:Human+Tumor+Assay+Systems+%28Laboratory+and+Diagnostic+Services+Panel%29:11/15/1999. Accessed June 2006.
20. Strauss G., Herndon J., Maddaus M., et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24 18S (2006) 7007
21. Fruehauf J. In vitro assay-assisted treatment selection for women with breast or ovarian cancer. Endocr Relat Cancer 9 (2002) 171-182
22. Doubre H., Cesari D., Mairovitz A., et al. Multidrug resistance-associated protein (MRP1) is overexpressed in DNA aneuploid carcinomatous cells in non-small cell lung cancer (NSCLC). Int J Cancer 113 (2005) 568-574
23. Volm M., Drings P., Mattern J., et al. Prognostic significance of DNA patterns and resistance-predictive tests in non-small cell lung carcinoma. Cancer 56 (1985) 1396-1403
24. Gregorc V., Ludovini L., Pistola L., et al. Relevance of p53, bcl-2, and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 39 (2003) 41-48
25. Ludovini V., Gregorc V., Pistola L., et al. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer. Lung Cancer 46 (2004) 77-85
26. d'Amico T., Aloia T., Moore M.-B., et al. Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann Thorac Surg 69 (2000) 882-886
27. Onn A., Correa A., Gilcrease M., et al. Synchronous overexpression of epidermal growth factor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 10 (2004) 236-243
28. Zhang W., Stoehlmacher J., Park D., et al. Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. Clin Colorectal Cancer 5 (2005) 124-131
29. Donnenberg V., and Donnenberg A. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 45 (2005) 872-877
30. Israeli D., Ziaei S., Gonin P., and Garcia L. A proposal for the physiologic significance of mdr1 and Bcrp1/Abcg2 gene expression in normal tissue regeneration and after cancer therapy. J Theoret Biol 232 (2005) 41-45
31. Schiller J., Harrington D., Belani C., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
32. Wieand H. Chemotherapy sensitivity and response assays: are the ASCO guidelines for clinical trial design too restrictive?. J Clin Oncol 23 (2005) 3643-3644
33. Nevins J., Petersen R., Mukherjee S., et al. A genomic strategy to refine prognosis in early stage non-small cell lung carcinoma (NSCLC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24 18S (2006) 7026
34. Leaf C. Why we're losing the war on cancer-and how to win it. Fortune 149 6 (2004) Mar 22